Literature DB >> 24815678

A child with unresectable biliary rhabdomyosarcoma: 48-month disease-free survival after liver transplantation.

M Paganelli1, M Beaunoyer, Y Samson, D Dal Soglio, J Dubois, M Lallier, F Alvarez.   

Abstract

We describe here a two-yr-old boy with biliary RMS successfully treated by chemotherapy and LT. The child presented with obstructive jaundice at 20 months of age. A mildly vascularized, non-calcified, partially cystic lesion was visualized in the left hepatic lobe. Solid infiltration of the common bile duct and of both left and right hepatic ducts was suspected. Liver biopsy suggested a botryoid-type embryonal RMS originating from the biliary tract. After extrahepatic spread of the tumor was excluded, a biliary drain was applied and neoadjuvant chemotherapy was started. After the treatment, although reduced in volume, the mass was still unresectable without aggressive surgery and gross residual disease. LT with a reduced segment II/III graft was performed four months after diagnosis. The patient received six cycles of adjuvant chemotherapy, and he is alive and recurrence-free 48 months post-transplantation. A posteriori, the transplant might have possibly been avoided with an aggressive resection with biliary reconstruction. Nevertheless, although the risk of the transplant has to be balanced against the chemoresponsiveness of the tumor, the four-yr disease-free survival of this patient suggests that, when coupled with effective chemotherapy, transplantation might be considered a potential treatment for unresectable biliary RMS.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  biliary rhabdomyosarcoma; liver transplantation; long-term survival; neoadjuvant chemotherapy

Mesh:

Substances:

Year:  2014        PMID: 24815678     DOI: 10.1111/petr.12279

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  3 in total

1.  Pediatric living donor liver transplantation for biliary embryonal rhabdomyosarcoma: a case report of a case showing disease-free survival over 2 years.

Authors:  Jung-Man Namgoong; Shin Hwang; Gil-Chun Park; Hyunhee Kwon; Suhyeon Ha; Seak Hee Oh; Kyung Mo Kim
Journal:  Korean J Transplant       Date:  2021-08-31

2.  Suboptimal outcome for patients with biliary rhabdomyosarcoma treated on low-risk clinical trials: A report from the Children's Oncology Group.

Authors:  Jamie M Aye; Wei Xue; Joshua D Palmer; David O Walterhouse; Michael A Arnold; Todd E Heaton; Rajkumar Venkatramani
Journal:  Pediatr Blood Cancer       Date:  2021-01-26       Impact factor: 3.167

3.  Treatment and outcome of the patients with rhabdomyosarcoma of the biliary tree: Experience of the Cooperative Weichteilsarkom Studiengruppe (CWS).

Authors:  Cristian Urla; Steven W Warmann; Monika Sparber-Sauer; Andreas Schuck; Ivo Leuschner; Thomas Klingebiel; Gunnar Blumenstock; Guido Seitz; Ewa Koscielniak; Jörg Fuchs
Journal:  BMC Cancer       Date:  2019-10-14       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.